Researchers from North Carolina State University have developed a new lithography technique that uses nanoscale spheres to create three-dimensional (3-D) structures with biomedical, electronic and photonic applications. The new technique is significantly less expensive than conventional methods and does not rely on stacking two-dimensional (2-D) patterns to create 3-D structures.
Culture
SAN FRANCISCO - The latest results of clinical trials of more than 125 patients testing an investigational personalized cellular therapy known as CTL019 will be presented by a University of Pennsylvania research team at the 56th American Society of Hematology Annual Meeting and Exposition.
An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML) - a poor-prognosis group with few options - report investigators from Dana-Farber Cancer Institute and M.D. Anderson Cancer Center.
Of 32 patients treated with the oral inhibitor ABT-199, five had eradication of their leukemia and several more had stable disease, according to Anthony Letai, MD, PhD, of Dana-Farber, senior author of the report.
(SAN FRANCISCO, DECEMBER 7, 2014) - Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology (ASH) Annual Meeting and Exposition.
PHOENIX -- In the treatment of multiple myeloma, the addition of carfilzomib to a currently accepted two-drug combination produced significantly better results than using the two drugs alone, according to a worldwide research team led by investigators from Mayo Clinic.
Their findings will be reported online Dec. 6 in the New England Journal of Medicine, and presented on Dec. 7 at the annual meeting of the American Society of Hematology (ASH), held in San Francisco.
SAN FRANCISCO, CA, December 6, 2014--In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance therapy after transplant can improve outcomes. The study, led by Craig H. Moskowitz, MD, Clinical Director of the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center, was presented today at the 56th Annual Meeting of the American Society of Hematology.
Scientists from Queen Mary University of London have found text messaging prevents one in six patients from forgetting to take, or stopping, their prescribed medicines.
The randomised trial, published today in the journal PLOS ONE, tested whether text messaging improved the use of blood pressure and cholesterol lowering medication for the prevention of heart attacks and stroke - the most common causes of death worldwide.
The Ku Klux Klan's failure to defeat the black civil rights moment is well documented, but the group's lesser-known legacy may be its lasting impact on the U.S. political system, according to a paper published in the December issue of the American Sociological Review.
CHICAGO (December 5, 2014): Malnutrition is an important factor predicting long-term survival in older patients undergoing pancreaticoduodenectomy (PD) (commonly called the Whipple procedure) to treat benign tumors and cysts of the pancreas as well as pancreatitis, according to new study results published in the December issue of the Journal of the American College of Surgeons.
ABBOTT PARK, Ill., Dec. 4, 2014 - Even in food-abundant industrialized countries like the U.S., an alarming number of people, particularly seniors, are in a state of diseased-associated malnutrition . Because of the impact on patient health, disease-associated malnutrition imposes a significant economic burden on society of $157 billion per year, according to new research published in a supplemental issue of the Journal of Parenteral and Enteral Nutrition (JPEN) and supported by Abbott .
Genetic mutations may cause more cases of amyotrophic lateral sclerosis (ALS) than scientists previously had realized, according to researchers at Washington University School of Medicine in St. Louis and Cedars-Sinai Medical Center in Los Angeles. The scientists also showed that the number of mutated genes influences the age when the fatal paralyzing disorder first appears.
Apixaban (trade name Eliquis) has been approved since July 2014 for acute treatment of adults with deep vein thrombosis or pulmonary embolism. In addition, the drug can be used for low-dose long-term treatment to prevent recurrent thrombosis or pulmonary embolism. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether in these cases the drug offers patients an added benefit over the appropriate comparator therapies.
PROVIDENCE, R.I. [Brown University] -- A "Viewpoint" published in JAMA urges readers to be patient with the new federal Open Payments Program database. The site, designed to report drug and device industry payments to physicians, debuted substantially incomplete, the authors wrote, but it is too important to dismiss before its shortcomings are addressed.
The widespread misconception that there are no proven treatments for Ebola virus disease has meant that simple treatments - especially intravenous fluids and electrolytes, which could reduce the number of deaths caused by the virus - have been neglected, according to a new Comment, published in The Lancet.
This news release is available in French.